Hip Osteoarthritis Osteoarthritis
Conditions
Interventions
This is a randomized, controlled, double blind, two arm study
The total sample will consist of forty individuals, divided into two groups
Group A will receive the intervention using high molecular weight hyaluronic acid 6 KDa, while Group B will also receive the intervention, but using low molecular weight hyaluronic acid 1 or 2 KDa
Viscosupplementation will be performed using permuted block randomization through the Research Randomizer software
The technique for performing hip joint injections under real time ultrasound guidance will consist of the following phases, after short term admission in a One Day Clinic setting, using appropriate as
Any joint effusion identified at this stage must be aspirated before the infiltration procedure itself
All patients will be evaluated on an outpatient basis at 1, 3, 6, and 12 months after treatment by a blinded specialist regarding the molecular weight of the hyaluronic acid used in viscosupplementati
Clinical evaluation will consist of the subjective global assessment of pain using the Visual Analog Scale VAS
Pain intensity, walking capacity, and daily activities will be assessed using the Lequesne Algofunctional Index
Additionally, the Western Ontario and McMaster Universities Osteoarthritis Index WOMAC will be used, which consists of a self reported questionnaire for the evaluation of patients with knee and hip os
Sponsors
Universidade do Estado do Rio de Janeiro
Hospital Universitário Pedro Ernesto
Eligibility
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: dult patients; aged between 18 and 70 years; of both sexes; with symptomatic primary hip osteoarthritis; classified as grade 3 according to the Kellgren & Lawrence scale
Exclusion criteria
Exclusion criteria: Patients who have previously undergone surgical treatment and have used other oral joint regeneration modulators for a period of less than 6 months;e.g., chondroitin sulfate, glucosamine, diacerein, and or collagen; patients with active inflammatory joint disease in the acute phase; e.g., rheumatoid arthritis, gout; patients with joint space over 2 millimetres; patients with avascular necrosis of the femoral head; patients with autoimmune disease or those unable to provide informed consent; all patients meeting these conditions will be categorically excluded from the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It`s expected to observe the functional outcomes of different molecular weights of hyaluronic acid used in the treatment of hip joint osteoarthritis through ultrasound guided intra articular injection, viscosupplementation | — |
Secondary
| Measure | Time frame |
|---|---|
| It`s expected to identify comorbidities that may influence outcomes during short-term follow-up after viscosupplementation treatment;It1s expected to describe the ultrasound-guided hip joint injection technique;It`s Expected to identify which radiographic grade of hip osteoarthritis demonstrates the best functional response to viscosupplementation treatment by comparing two types of hyaluronic acid that differ in molecular weight | — |
Countries
BR
Contacts
Public ContactAndre Pessoa
Universidade do Estado do Rio de Janeiro
Outcome results
None listed